# Accepted Manuscript

The Use of Cannabis in Response to the Opioid Crisis: A Review of the Literature

Marianne Beare Vyas, RN, MSN, ANP-BC, PhD candidate, Virginia T. LeBaron, PhD, APRN, FAANP, Assistant Professor of Nursing, Aaron Gilson, PhD, MSSW, Research Program Manager and Senior Scientist

Please cite this article as: Vyas MB, LeBaron VT, Gilson A, The Use of Cannabis in Response to the Opioid Crisis: A Review of the Literature, *Nursing Outlook* (2017), doi: 10.1016/j.outlook.2017.08.012.

Title: The Use of Cannabis in Response to the Opioid Crisis: A Review of the Literature

Authors: Marianne Beare Vyas RN, MSN, ANP-BC [a], Virginia T. LeBaron PhD, APRN, FAANP [b], Aaron Gilson, PhD, MSSW [c]

[a] Marianne Beare Vyas, PhD candidate at the University of Virginia, School of Nursing. 202 Jeanette Lancaster Way, Charlottesville, VA 22903. Mjb4bq@virginia.edu
[b] Virginia T. LeBaron, Assistant Professor of Nursing, University of Virginia School of Nursing, McLeod 5040, 202 Jeanette Lancaster Way, Charlottesville, VA 22903. vlebaron@virginia.edu
[c] Aaron M. Gilson, Research Program Manager and Senior Scientist, Pain & Policy Studies Group / WHO Collaborating Center. Carbone Cancer Center, University of Wisconsin-Madison, 1300 University Avenue, Madison, WI 53706. amgilson@wisc.edu

Corresponding Author: Marianne Beare Vyas mjb4bq@virginia.edu

Abstract

Background: A staggering number of Americans are dying from overdoses attributed to prescription opioid medications (POMs). In response, states are creating policies related to POM harm reduction strategies, overdose prevention, and alternative therapies for pain management, such as cannabis (medical marijuana). However, little is known about how the use of cannabis for pain management may be associated with POM use.

Purpose: The purpose of this article is to examine state medical cannabis (MC) use laws and policies and their potential association with POM use and related harms.

Methods: A systematic literature review was conducted to explore U.S. policies related to MC use and the association with POM use and related harms. Medline, PubMed, CINAHL, and Cochrane databases were searched to identify peer-reviewed articles published between 2010 – 2017. Using the search criteria 11,513 records were identified, with 789 abstracts reviewed, and then 134 full-text articles screened for eligibility.

Results/Discussion: Out of 134 articles, 10 articles met inclusion criteria. Four articles were cross-sectional online survey studies of MC substitution for POM, 6 were secondary data analyses exploring state level POM overdose fatalities, hospitalizations related to MC or POM harms, opioid use disorder admissions, motor vehicle fatalities, and Medicare and Medicaid prescription cost analysis. The literature suggests MC laws could be associated with decreased POM use, fewer POM-related hospitalizations, lower rates of opioid overdose, and reduced national healthcare expenditures related to POM overdose and misuse. However, available literature on the topic is sparse and has notable limitations.

Conclusions: Review of the current literature suggests states that implement MC policies could reduce POM associated mortality, improve pain management, and significantly reduce health

care costs. However, MC research is constrained by federal policy restrictions, and more research related to MC as a potential alternative to POM for pain management, MC harms, and its impact on POM related harms and healthcare costs should be a priority of public health, medical, and nursing research.

Background and Significance

The United States (U.S.) is currently in the midst of an opioid crisis, with an estimated 3.8 million adults misusing prescription opioid medications (POM) (Center for Behavioral Health Statistics and Quality [CBHSQ], 2016). . Reports suggest that POM misuse can progress to heroin use (Jones, 2013; Muhuri, Gfroerer, & Davies, 2013; Cicero, Ellis, Suratt, & Kurtz, 2014; Rudd, Aleshire, Zibbel, & Gladden, 2016), and a 200% increase rate of death from opioid overdose (Rudd, Aleshire, Zibbel, & Gladden, 2016) POMs were involved in over 15,000 deaths in 2015, and the most common POMs involved were oxycodone, hydrocodone, and methadone (Rudd et al., 2016; Centers for Disease Control [CDC], 2016). A public health state of emergency has even been declared in at least six states within the U. S. (Schneider, 2016; Turque, 2017; Allen, 2017). However, despite the national demand for harm reduction strategies such as reforming prescribing practices, using reversal drug naloxone, and finding alternatives to POMs for pain, the opioid epidemic remains a major public health crisis (National Institute on Drug Abuse [NIDA], 2015); CDC, 2016).

The Institute of Medicine's (IOM) 2011 report estimated pain affects at least 100 million American adults, costs society up to $635 billion annually, and reduces quality of life (IOM, 2011). Interestingly, even when considering the misuse of POMs (e.g., taking not as prescribed, for example taking more tablets than directed), research shows that the most common motivation is to relieve physical pain (Hughes et al., 2016). Therefore, an integrative approach to pain

management, involving safer, non-addictive, alternatives to POMs, are essential to continue to treat patients in pain.

Cannabis has been studied as an emerging therapy for pain control (Abrams et al., 2007; Andreae et al., 2015; Wallace et al., 2015; Ware et al., 2010; Whiting et al., 2015; Wilsey et al., 2013), and patients are using it for pain control both with and without concurrent POM use (Perron et al., 2015). Cannabis remains a Schedule I controlled substance under federal law; nonetheless, cannabis is currently the most commonly used illicit drug with 22.2 million Americans (12 years and older) self-reported as current users (used in the past 30 days), either for medicinal or recreational purposes (CBHSQ, 2016). The National Academies of Science, Engineering and Medicine (NASEM) concluded that there is "substantial evidence that cannabis is an effective treatment for chronic pain in adults," (NASEM, 2016, p.90). Medicinal use of cannabis (MC) is not without risks, and more research is needed to formalize dose, route, concentration, and safety information. Research on cannabis remains challenging, however, due to restrictive policies related to its status as a controlled substance under federal law (NIDAa, 2016; NIDAb, 2016; Thomas & Pollard, 2016). Despite this need for further research, cannabis has become legal for medicinal use in 29 states and the District of Columbia (D.C.) (National Council of State Legislators [NCSL], 2017). There is a critical knowledge gap regarding how MC policies will affect pain management and POM use across the U.S. To address this gap, a systematic review of the current literature was conducted to explore the research question: Is there an association between MC laws and POM use and harms?

Methods

Search Strategy

The term 'opioid epidemic' can refer to both POM and illicit opioids (such as heroin). This review and the articles selected focus on POMs and POM-related harms such as overdose, opioid use disorder (OUD) and the associated healthcare costs -- not on harms related only to illicit opioids.

A literature review was conducted by searching the electronic databases Medline, CINAHL, PubMed, Cochrane Review, and Google Scholar. The keyword opioid was used with additional MeSH terms including opioid analgesic, opioid-related disorders, prescription drug misuse, opioid use disorder, opioid policy, overdose, and prescription pain medication. Cannabis and medical marijuana were also used as a keyword search terms, including MeSH terms of cannabis and pain, cannabis and opioids, alternative therapies, substance use disorder, cannabis use disorder, and cannabis policy. After separate searches of terms related to cannabis and terms related to opioids were completed, the two searches of opioid and cannabis were combined to find articles with both terms utilized. The health sciences librarian replicated the literature search for completeness.

Inclusion search criteria included peer-reviewed articles published in English between 2010 and July 2017 with applicability to the research question, as well as policy overview articles addressing state level statistics related to costs, overdose, opioid or cannabis use disorders in states with MC laws. The publication timeline was selected to: 1) encompass the period when POM sales peaked and began to decline as a result of national recognition of the public health risk they posed (Staffa, 2017); 2) the publication of the landmark IOM (2011) report identifying pain as a major public health problem requiring treatment; 3) and the date by which (2010) approximately half of the current state medical cannabis laws had been initiated (NCSL, 2017). Articles were excluded if they were not peer-reviewed, discussed laws and

policies of countries other than the U.S., covered topics related either to POM or MC, but not to

both, related only to illicit opioids (e.g., heroin), did not include an analysis after the state passed

MC laws, or were not relevant to the research question.

Sample

A total of 11,513 possible articles were identified through the initial keyword search.

After duplicates were removed, 789 article abstracts were screened for applicability. Out of 789,

a total of 379 articles were removed for lack of peer review, because they were editorial/opinion

articles, or because they did not relate to the research question. Of the 410 articles remaining,

abstracts were screened and 276 articles were excluded for being either single subject (opioids or

cannabis), or not applying to the research question. The first author completed a full-text review

of the remaining articles (n=134) to verify they met eligibility criteria (Table 1), resulting in 13

articles. When each of the 13 publications were reviewed, three were removed for being

international studies. As a result, a total of 10 articles fully met inclusion criteria and comprise

the sample for this review.

Findings/Results

Table 2 summarizes the 10 studies that met the inclusion criteria. It is important to note

that articles use various terms to describe related, but not necessarily identical, concepts, such as

opioid misuse versus opioid abuse. For clarity, the terminology used in the original article is

utilized throughout this report.

Of these 10 studies reviewed, two studies specifically addressed the substitution of MC

for POM (Sexton et al., 2016, Corroon et al., 2017). Sexton et al. (2016) found that in a survey of

MC patients (n=1429) in Washington, nearly 60% reported substituting cannabis for any

prescription drug, and 25% specifically for pain medication, including POMs, many doing so

without physician supervision. Corroon et al. (2017) surveyed 2,774 MC patients online and through a Washington state dispensary. 46% reported using cannabis as a substitute for prescription drugs, most commonly POMs. When states with MC laws were compared to those without, there were no differences in prescription drug substitutions based on access to MC (Corroon et al., 2017).

In addition to substitution of MC for POMs, two studies reported MC use was associated with decreased POM use (Boehnke et al., 2016; Reiman, 2017). Boehnke et al. (2016) studied changes in opioid use and quality-of-life in MC users in Michigan through an online survey and found MC use was associated with a 64% decrease in POM use, and 45% improvement in quality-of-life. Reiman et al. (2017) found that 97% of those MC users surveyed in California reported decreasing use of POMs when concurrently using MC, and 93% reported preferring MC to POMs for pain relief without a specific reason cited.

Powell, Pacula, & Jacobson (2015) studied the impact of medical cannabis laws on opioid related harms by reviewing treatment admissions for POM abuse and state level POM overdose deaths from 1999-2013; they concluded states permitting medical cannabis dispensaries had a relative decrease in both POM addictions (as measured by treatment facility admissions) and POM overdose deaths compared to states that did not. Powell, Pacula, & Jacobson (2015) found a decrease in POM overdose and POM addiction only in states with MC dispensaries, suggesting actual availability of MC is the factor that reduces POM overdose and addiction levels, not simply having a MC law that makes it legal to use.

Bachhuber et al. (2014) analyzed POM overdose deaths from three states that had medical cannabis laws prior to 1999 (California, Oregon, and Washington), as well as ten states that implemented medical cannabis laws between 1999 and 2010, and nine states that did not

have medical cannabis laws effective until after 2010. The authors reported that the age-adjusted

opioid mortality rate was 24.8% lower in states with MC laws *(p=0.003)* and concluded MC laws

could be associated with lower rates of POM overdose deaths.

The policy literature includes several examples of analyses indicating that access to MC

use may result in a decline in POM prescriptions and expenditures. Bradford & Bradford (2017)

found Medicaid beneficiaries filled fewer prescriptions, including those for POMs, in states that

passed MC laws. They extrapolated their findings nationally and estimated that if all states had

MC laws in 2014 there would be a $1.01 billion savings in prescription drug costs. Importantly,

this analysis did not differentiate cost savings specifically related to POM, but the authors

performed a sub analysis in nine broad clinical diagnosis areas (e.g., anxiety, depression,

glaucoma, nausea, pain, psychosis, seizure, sleep, spasticity), all of which were associated with

the use of cannabis and found a significant difference in those in a pain management category

($p<0.01$). The same authors also previously evaluated the use of prescription medications by

Medicare Part D recipients and found that the use of POMs, declined once MC laws were

initiated in the state (Bradford & Bradford, 2016).

A recent study by Shi (2017) analyzed the association between state MC policy and

hospital admissions related to cannabis and opioids in 27 states. MC legalization was associated

with a 23% and 13% reduction in hospitalizations for opioid use disorder related to POM, and

opioid overdose, respectively. There was no evidence that MC policy implementation was

associated with subsequent increase in cannabis-related hospitalizations (Shi, 2017). Kim et al.

(2016) analyzed drivers in fatal car accidents in 18 states before and after MC laws were

initiated; they found a significantly decreased number of opioid positive tests among 21-40 year

olds in states after MC laws had been passed (OR-0.50; 95% CI, 0.67; interaction $p<0.001$).

However, the authors did not differentiate opioid positivity from POM versus opioid positivity from illicit opioids, such as heroin.

Discussion and Recommendations

All 10 studies reviewed indicate a connection between MC and reduced POM harms. The key outcomes measured included opioid related overdoses, fatalities, POM abuse, hospitalizations, use, and cost. POM abuse was typically operationalized as admission to treatment facilities or hospitalizations for POM related harms. States with laws allowing MC use were found to have lower POM overdose mortality rates (Bachhuber et al., 2014), especially in states with active, legal MC dispensaries (Powell et al., 2015), a decrease in POM use (Boehnke et al., 2016; Sexton et al., 2016; Corroon et al., 2017; Reiman et al., 2017), cost savings for prescription drugs for which cannabis could serve as an alternative (Bradford & Bradford, 2016; Bradford & Bradford, 2017), a decrease in opioid positivity in fatally injured drivers (Kim et al., 2016), and reduced POM related hospitalizations (Shi, 2017). This literature review is consistent with international research from Canada (Lucas et al., 2013; Lucas & Walsh, 2017) and Israel (Haroutounian et al., 2016) that concluded patients are substituting MC for POMs as an alternative pain management strategy (Lucas et al., 2013, Haroutounian et al., 2016; Lucas & Walsh, 2017).

One potential explanation for these findings is that there are behavioral, anatomical, and biochemical similarities between the opioid receptor system and the cannabinoid receptor system (Bushlin, Rozenfield, & Devi, 2010). This could have implications not only for the substitution of POMs with MC, but also a reduction in POM use when patients use MC. Although the long term risks of MC legalization are unclear, there have been zero reported deaths directly related to

cannabis overdose, whereas there were 33,091 deaths related to all opioids in 2015, over 15,000 of which were attributed to POMs such as hydrocodone, oxycodone and fentanyl (CDC, 2015; Rudd et al., 2016). However, Colorado, a state with both liberal MC and recreational cannabis laws, has seen an increase in tetrahydrocannabinol (THC, the primary psychoactive component of cannabis) positive drivers in traffic fatalities, (Reed, 2016).

This review underscores the importance of multiple harm reduction strategies, including exploring integrative and alternative therapies for pain management, to reduce the number of deaths associated with POM. To our knowledge, this is the first literature review to examine if there is an association between MC laws and POM use, abuse, cost, and overdose in the U.S. More research is needed to strengthen preliminary empirical findings that access to MC is a viable pain management strategy for creating positive risk/benefit profiles for patients with chronic pain while reducing POM associated harms from therapeutic use.

Limitations

There are important limitations to the 10 studies reviewed. The primary limitation involves study design. Four studies exclusively relied upon self-report survey data to evaluate whether MC patients were reducing their POM use and why. Participants providing self-report data through Internet surveys can be subject to both selection bias and recall bias. The self-report data presented in these studies provides little clarity regarding the reasons patients substituted MC for POM; for example, pain level or side effect profiles were not primary reasons discussed in any of the studies, and quality-of-life was an outcome in only one study (Boehnke et al., 2016). Additionally, there is no ability to differentiate outcomes resulting from recreational use, as compared to medical use, of either cannabis or POMs.

These studies were all descriptive, and did not empirically test the effectiveness of MC in actually reducing pain, or the impact of potential MC related harms, which would be important considerations for clinical practice. None of the studies considered the influence of clinical diagnosis (e.g., are results different for participants with myofascial pain versus pain from the disease of cancer?). Additionally, outcomes measures were conceptualized and operationalized inconsistently across studies, making it difficult to compare findings or draw general conclusions. For example, "opioid abuse" or "problematic opioid use" was determined by admissions to treatment facilities (Powell et al., 2015), opioid related hospitalizations (Shi, 2017), or a combination of Treatment Episode Data Set (TEDS) and National Vital Statistics System (NVSS) data (Powell et al., 2015). Finally, clear differentiation between licit opioids (such as POMs) and illicit opioids (such as heroin) is lacking in several of the studies.

Most importantly, the literature reviewed compared the medical use of cannabis to POM related harms. This is problematic for two key reasons. First, there was a lack of equal consideration for MC related harms in the study designs. Second, POM harms such as overdose, admission to treatment facilities, or hospitalizations are most often consequences of *non-medical* (or recreational) POM misuse, versus legitimate POM use for medical reasons. Therefore, conclusions based on comparing medical versus non-medical use and harms of two different substances must be interpreted with significant caution.

Implications for Nursing Practice.

Health practitioners need to be a strong voice urging policy makers and research funding entities to support further investigation of MC as an alternative pain management and harm reduction strategy for patients. Recent large scale NIH funding for MC research is an important

first step (NIH, 2017). Nurses should be advocates for patient-centered, integrative pain

management approaches, which may include the safe and appropriate prescribing of POMs when

needed, and conceivably the use of MC as further information becomes available, which is

already being done in some states. However, there is still much unknown regarding the potential

harms of MC, and more data are needed to understand potential complications of MC such as

respiratory disease, substance abuse, psychiatric disorders and impaired cognitive function.

The official American Nurses Association (ANA) position statement on MC is that

cannabis should be reclassified as a federal Schedule II controlled substance for purposes of

facilitating research. The ANA also advocates for the development of prescribing standards with

specific dose, route, side effect profile, and indications for cannabis preparations, as well as

evidence-based standards for its use (ANA, 2016b). It is important for nurses to remember that

MC is still illegal under federal law, and tolerance of more liberal state cannabis laws can change

at any time given national politics and the interests of the sitting Attorney General. Federal

prosecution against practitioners who prescribe or dispense MC is always possible as long as

cannabis remains federally classified under Schedule I, and this risk must be taken into

consideration prior to making any clinical recommendations.

Conclusions

The opioid epidemic is a public health crisis that is at least partially driven by harms

associated with POM use. States are passing laws allowing use of MC and patients are using

MC, but currently there is little understanding of how this influences POM use or of MC related

harms. This literature review provides preliminary evidence that states with MC laws have

experienced reported decreases in POM use, abuse, overdose, and costs. However, existing

evidence is limited by significant methodological shortcomings, so general conclusions are difficult to draw.

The use of MC as an alternative to POMs for pain management warrants additional empirical attention as a potential harm reduction strategy. NASEM (2016) recommends more clinical trials to elucidate appropriate forms, routes of administration, and combination of products for treating pain, but access to MC products to fully evaluate these questions is challenging due to federal regulations. However, the recently funded National Institute of Health longitudinal study to research the impacts of MC on opioid use is a critical step in the right direction (NIH,2017; Williams, 2017). MC's potentially as an alternative treatment modality, to help mitigate the major public health opioid crisis, could be a missed opportunity if data on safety, efficacy, and outcomes are not collected and explored. Healthcare practitioners, particularly nurses who are charged with ensuring patient comfort, have a vested interest in providing viable alternatives to POMs when appropriate, as part of an integrative approach to pain management, and must advocate for more research to better understand the public health implications and risks and benefits of such alternatives.

References

Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H, Press, S,…Peterson, K. L. (2007).

Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-

controlled trial. *Neurology, 68*(7), 515-521. doi:

10.1212/01.wnl.0000253187.66183.9c

Allen, G. (11 August, 2017). From Alaska to Florida, states respond to opioid crisis with

emergency declarations. Retrieved from http://www.npr.org/sections/health-

shots/2017/08/11/542836709/from-alaska-to-florida-states-respond-to-opioid-crisis-with-

emergency-declaratio

American Nurses Association. (2016a). The opioid epidemic: addressing the growing drug

overdose problem. ANA Issue Brief. Retrieved from

https://www.nursingworld.org/DocumentVault/Health/ANA-IssueBrief-Opioid-

Epidemic.pdf

American Nurses Association. (2016b). Therapeutic use of marijuana and related cannabinoids.

Retrieved from http://www.nursingworld.org/MainMenuCategories/Policy-

Advocacy/Positions-and-Resolutions/ANAPositionStatements/Position-Statements-

Alphabetically/Therapeutic-Use-of-Marijuana-and-Related-Cannabinoids.pdf

Andreae, M. H., Carter, G. M., Shaparin, N., Suslov, K., Ellis, R. J., Ware, M. A.,…& Sacks, H.

(2015). Inhaled cannabis for chronic neuropathic pain: A meta-analysis of individual

patient data. *The Journal of Pain 16*(12), 1221-1232. doi: 10.1016.jpain.2015.07.009

Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L. (2014). Medical cannabis

laws and opioid analgesic overdose mortality in the United States, 1999-2010. *JAMA

Internal Medicine 174*(10), 1668-1673. doi: 10.1001/jamainternmed.2014.4005

Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016). Medical cannabis use is associated with

    decreased opiate medication use in a retrospective cross-sectional survey of patients with

    chronic pain. *Journal of Pain, 17*(6), 739-744.

Bradford, A. C. & Bradford, W. D. (2016). Medical marijuana laws reduce prescription

    medication use in Medicare part D. *Health Affairs 35*(7), 1230-1236. doi:

    10.1377/hlthaff.2015.1661

Bradford, A. C. & Bradford, W. D. (2017). Medical marijuana laws may be associated with a

    decline in the number of prescriptions for Medicaid enrollees. *Health Affairs 36*(5), 945-

    951. doi: 10.1377/hlthaff.2016.1135

Center for Behavioral Health Statistics and Quality [CBHSQ]. (2016). *Key substance use and*

    mental health indicators in the United States: results from the 2015 National Survey on

    Drug Use and Health. Substance Abuse and Mental Health Services Administration.

    Rockville, MD. Retrieved from

    https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-   FFR1-

    2015/NSDUH-FFR1-2015.htm

Centers for Disease Control [CDC] (2015). Multiple cause of death1999-2014 on CDC

    WONDER online database released 2015. Retrieved from http://wonder.cdc.gov/mcd-

    icd10.html

Centers for Disease Control [CDC] (2016). Prescription opioid overdose. Retrieved from

    https://www.cdc.gov/drugoverdose/data/overdose.html

Cerdá, M., Wall, M., Feng, T., Keyes, K. M., Sarvet, A., Schulenberg, J., …& Hasin, D. S.

    (2017). Association of state recreational marijuana laws with adolescent marijuana use.

    JAMA Pediatrics 171(2), 142-149. doi: 10.1001/jamapediatrics.2016.3624

Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). The changing face of heroin use
in the United States: a retrospective analysis of the past 50 years. *JAMA Psychiatry*, 71,
821-826.

Corroon, J. M., Mischley, L. K., & Sexton, M. (2017). Cannabis as a substitute for prescription
drugs- a cross-sectional study. *Journal of Pain Research, 10*, 989-998. doi:
10.2147/JPR.S134330

Haroutounian, S., Ratz, Y., Ginosar, Y., Furmanov, K., Saifi, F., Medidan, R., & Davidson, E.
(2016). The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic
pain: A prospective open-label study. *Clinical Journal of Pain 32*(12), 1036-1043. doi:
10.1097/AJP.0000000000000364

Hasin, D. S., Sarvet, A. L., Cerdá, M., Keyes, K. M., Stohl, M., Galea, S., & Wall, M. M. (2017).
US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws 1991-
1992 to 2012-2013. *JAMA Psychiatry 74*(6), 579-588. Doi:
10.1001/jamapsychiatry.2017.0724

Hughes, A., Williams, M. R., Lipari, R. N., Bose, J., Copello, E. A. P., & Kroutil, L. A. (2016).
Prescription drug use and misuse in the United States. Results from the 2015 national
survey on drug use and health. NSDUH Data Review. Retrieved from
https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-
2015.htm

Institute of Medicine. (2011). *Relieving Pain in America: A blueprint for transforming
prevention, care, education and research.* The National Academies Press, Washington D.
C.

Jones, C. M. (2013). Heroin use and heroin use risk behaviors among nonmedical users of

prescription opioid pain relievers-United States, 2002-2004 and 2008-2010. *Drug and*

Alcohol Dependence, 132, 95-100.

Kim, J. H., Santaella-Tenorio, J., Mauro, C., Wrobel, J., Cerdá, M., Keyes, K. M., …& Li, G.

(2016). State medical marijuana laws and the prevalence of opioids detected among

fatally injured drivers. *American Journal of Public Health 106*(11), 2032-2037. doi:

10.2105/AJPH.2016.303426

Light, M. K., Orens, A., Lewandowski, B., & Pickton, T. (2014). Market size and demand for

marijuana in Colorado. The Marijuana Policy Group.

Lucas, P. (2012). Cannabis as an adjunct to or substitute for opiates in the treatment of chronic

pain. *Journal of Psychoactive Drugs, 44*(2), 125-133. doi:

10.1080/02791072.2012.684624

Lucas, P., Reiman, A., Earleywine, M., McGowan, S. K., Oleson, M., Coward, M. P., &

Thomas, B. (2013). Cannabis as a substitute for alcohol and other drugs: A dispensary-

based survey of substitution effect in Canadian medical cannabis patients. *Addiction*

Research and Theory 21(5), 435-442. doi: 10.3109/16066359.2012.733465

Lucas, P., & Walsh, Z. (2017). Medical cannabis access, use, and substitution for prescription

opioids and other substances: a survey of authorized medical cannabis patients.

International Journal on Drug Policy 42, 30-35. doi: 10.1016/j.drugpo.2017.01.011

Lynne-Landsman, S. D., Livingston, M. D., & Wagenaar, A. C. (2013). Effect of state medical

marijuana laws on adolescent marijuana use. *American Journal of Public Health 103*(8),

1500-1506. doi: 10.2105/AJPH.2012.301117

Mason, W. A., Fleming, C. B., Ringle, J. L., Hanson, K., Gross, T. J., & Haggerty, K. P. (2016). Prevalence of marijuana and other substance use before and after Washington State's change from legal medical marijuana to legal medical and nonmedical marijuana: Cohort comparisons in a sample of adolescents. *Substance Abuse 37*(2), 330-335. doi: 10.1080/08897077.2015.1071723

Muhuri, P. D., Gfroerer, J. C., & Davies, M. C. (2013). Associations of nonmedical pain reliever use and initiation of heroin use in the United States. Substance Abuse and Mental Health Services Administration, Centers for Behavioral Health Statistics and Quality, Rockville, MD. Retrieved from http://www.samhsa.gov/data/

National Academies of Sciences, Engineering, and Medicine [NASEM]. (2017). *The health effects of cannabis and cannabinoids.* Washington DC, National Academies Press.

NASEM (2017). *Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use.* The National Academies Press: Washington DC. Prepublication copy, unedited proof. doi: 10.17226/24781

National Council of State Legislators. (2017). State medical marijuana laws. Retrieved from http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx

National Institute on Drug Abuse (2015). Prescription and over-the-counter medication. Retrieved from https://www.drugabuse.gov

National Institute on Drug Abuse [NIDA]a. (2016). *NIDA Mission*. Retrieved from https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-institute-drug-abuse-nida

National Institute on Drug Abuse [NIDA]b. (2016). *NIH Research on marijuana and*

   cannabinoids. Retrieved from https://www.drugabuse.gov/drug-abuse/marijuana/nih-

   research-marijuana-cannabinoids.

National Institute of Health [NIH] (2017). Research Portfolio Online Reporting Tools. Project

   Number 1R01DA044171-01A1. Does medical cannabis reduce opioid analgesics in

   HIV+ and HIV- adults with pain? Retrieved from

   https://projectreporter.nih.gov/project_info_description.cfm?aid=9424500&icde=357057

   68&ddparam=&ddvalue=&ddsub=&cr=13&csb=ORG&cs=ASC&pball=

Paulozzi, L. J., Mack, K. A., & Hockenberry, J. M. (2014). Vital signs: variation among states in

   prescribing of opioid pain relievers and benzodiazepines, United States, 2012. *MMWR*

   Weekly Report 63(26), 563-568.

Perron, B. E., Bohnert, K., Perone, A. K., Bonn-Miller, M. O., & Ilgen, M. (2015). Use of

   prescription pain medications among medical cannabis patients: comparison of pain

   levels, functioning, and patterns of alcohol and other drug use. *Journal of Studies on*

   Alcohol and Drugs 76(3), 406-413.

Powell, D., Pacula, R., & Jacobson, M. (2015). Do medical marijuana laws reduce addictions

   and deaths related to pain killers? RAND Corporation. Retrieved from

   http://works.bepress.com/david_powell/17/

Reed, J. K. (2016, March). Marijuana legalization in Colorado: Early Findings. A report pursuant

   to Senate bill 13-283. Retrieved from https://cdpsdocs.state.co.us/ors/docs/reports/2016-

   SB13-283-Rpt.pdf

Reiman, A., Welty, M., & Solomon, P. (2017). Cannabis as a substitute for opioid-based pain

medication: patient self-report. *Cannabis and Cannabinoid Research, 21*, 160-166. doi:

10.1089/can.2017/0012

Rudd, R. A., Aleshire, N., Zibbel, J. E., & Gladden, R. M. (2016). Increases in drug and opioid

overdose deaths-United States, 2000-2014. *Morbidity and Mortality Weekly Report,*

64(50-51), 1378-1382. Doi: 10.15585/mmwr.mm6450a3

Santaella-Tenorio, J., Maura. C. M., Wall, M. M., Kim, J. H., Cerdá, M., Keyes, K. M.,…&

Martins, S. S. (2016). US traffic fatalities, 1985-2014, and their relationship to medical

marijuana laws. *American Journal of Public Health 107*(2), 336-342. doi:

10.2105/AJPH.2016.303577

Schneider, G. S. (2016, November 21). Virginia declares opioid emergency, makes antidote

available to all. *The Washington Post*. Retrieved from

https://www.washingtonpost.com/local/virginia-politics/virginia-declares-opioid-

emergency-makes-antidote-available-to-all/2016/11/21/f9b4f348-b00e-11e6-be1c-

8cec35b1ad25_story.html?utm_term=.f26509c07f7a

Secades-Villa, R., Garcia-Rodriguez, O., Jin, C. J., Wang, S., & Blanco, C. (2015). Probability

and predictors of the cannabis gateway effect: a national study. *International Journal of*

Drug Policy, 26(2), 135-142. Doi: 10.1016/j.drugpo.2014.07.11

Sexton, M., Cuttler, C., Finnell, J. S., & Mischley, L. K. (2016). A cross-sectional survey of

medical cannabis users: patterns of use and perceived efficacy. *Cannabis and*

Cannabinoid Research 1.1, 131-138. doi: 10.1089.can.2016.0007

Shi, Y. (2017). Medical marijuana policies and hospitalizations related to marijuana and opioid

pain reliever. *Drug and Alcohol Dependence 173*, 144-150. doi:

10.1016.j.drugalcdep.2017.01.006

Substance Abuse and Mental Health Services Administration. (2016). Prescription drug use and

misuse in the United States: Results from the 2015 National Survey on Drug Use and

Health. Retrieved from http://www.samhsa.gov

Staffa, (2017).

Thomas, B. F., & Pollard, G. T. (2016). Preparation and distribution of cannabis and cannabis-

derived dosage formulations for investigational and therapeutic use in the United States.

Frontiers in Pharmacology 31(7), 285. Doi: 10.3389/fphar.2016.00285

Turque, B. (2017, March 1). Maryland governor declares state of emergency for opioid crisis.

The Washington Post. Retrieved from https://www.washingtonpost.com/local/md-

politics/hogan-declares-opioid-state-of-emergency/2017/03/01/5c22fcfa-fe2f-11e6-99b4-

9e613afeb09f_story.html?utm_term=.d6bb75c508cd

Wallace, M. S., Marcotte, T. D., Umlauf, A., Gouaux, B., & Atkinson, J. H. (2015). Efficacy of

inhaled cannabis on painful diabetic neuropathy. *Journal of Pain, 16*(7), 616-627.

doi:https://dx-doi-org.proxy.its.virginia.edu/10.1016/j.jpain.2015.03.008

Ware, M. A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., …Collet, J.(2010).

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *Canadian

Medical Association Journal, 182*(14), E694-E701. Doi: 10.1503/cmaj.091414

Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V.,…&

Kleijnen, J. (2015). Cannabinoids for medical use: A systematic review and meta-

analysis. *JAMA 313*(24), 2456-2473. Doi: 10.1001/jama.2015.6358

Williams, T. (2017, August 12). A government health agency is funding the first-ever study on

medical marijuana's impact on opioid abuse. Market Watch. Retrieved from

http://www.marketwatch.com/story/a-government-health-agency-is-funding-the-first-

ever-study-on-medical-marijuanas-impact-on-opioid-abuse-2017-08-11

Wilsey, B., Marcotte, T., Deutch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013). Low-dose

vaporized cannabis significantly improves neuropathic pain. *The Journal of Pain, 14*(2),

136-148. doi: 10.1016/j.jpain.2012.10.009

Table 1. Literature search flow diagram

```
┌─────────────────────────────────┐
│ Records identified through Medline│
│ (n=3,068), PubMed (n=2,351),     │
│ CINAHL (n=6,094), and Cochrane   │
│ (n=0)                            │
│ (n = 11,513 )                    │
└─────────────────────────────────┘
              │
              ▼
┌─────────────────────────────────┐      ┌──────────────────────┐
│ Records after duplicates removed,│      │ Citations excluded, non-│
│ time limited to 2010-2017 and    │─────▶│ peer reviewed, or      │
│ English language limits added    │      │ opinion/editorial      │
│ (n = 789 )                       │      │ (n =379 )              │
└─────────────────────────────────┘      └──────────────────────┘
              │
              ▼
┌─────────────────────────────────┐      ┌──────────────────────┐
│                                 │      │ Abstracts excluded for │
│ Abstracts screened              │      │ single subject (only   │
│ (n =410 )                       │─────▶│ opioid or only cannabis),│
│                                 │      │ or not applicable to   │
│                                 │      │ research question.     │
│                                 │      │ (n =276 )              │
└─────────────────────────────────┘      └──────────────────────┘
              │
              ▼
┌─────────────────────────────────┐      ┌──────────────────────┐
│ Full-text articles assessed      │      │ Full-text articles     │
│ for eligibility                 │─────▶│ excluded, poor fit with│
│ (n =  134 )                     │      │ research question      │
│                                 │      │ (n = 121  )            │
└─────────────────────────────────┘      └──────────────────────┘
              │
              ▼
┌─────────────────────────────────┐      ┌──────────────────────┐
│ Studies included in              │      │ Eliminated for         │
│ literature review               │─────▶│ International focus     │
│ (n = 13  )                      │      │ (n = 3 )               │
└─────────────────────────────────┘      └──────────────────────┘
              │
              ▼
┌─────────────────────────────────┐
│ Studies included in final        │
│ literature review               │
│ (n = 10 )                       │
└─────────────────────────────────┘
```

Table 2. Literature Table

Study/Title	Purpose	Study Design	Data sources	Location	Sample	Outcome Measure	Key Results and Conclusions
Bradford & Bradford (2017) Medical marijuana laws may be associated with ad decline in the number of prescriptions for Medicaid enrollees	Address the association between MC laws and number of prescriptions filled by Medicaid beneficiaries	Primary explanatory bivariate model	Medicaid fee-for-service prescription data, state drug utilization data	24 states	24 states with medical marijuana law; 9 clinical areas of prescription drugs for which MC could be a substitute	State Drug Utilization from CMS[3] Medicaid enrollees in nine condition categories,	Medicaid cost savings associated with MC laws =$19.825 million per state = Total of $3.89 billion nationally if all states had MC laws. Medicaid beneficiaries in states with MC laws will fill fewer prescriptions
Corroon, Mischley, & Sexton (2017) Cannabis as a substitute for prescription drugs- a cross-sectional study	Survey cannabis users for intentional substitutions of cannabis for prescription drugs	Cross-sectional survey	Anonymous questionnaire	WA, CA, OR, CO; recruit via social media and cannabis dispensary in WA,	N=2,774	Anonymous online survey, self selected	46% used cannabis as substitute for prescription drug, most commonly POM. No diff between states with medical cannabis laws vs none. Substitutions are happening, state laws may not influence individual decision making
Reiman, Welty, & Solomon (2017) Cannabis as a substitute for opioid-	Data gathering about the use of cannabis as	Cross-sectional survey	Self reported data HelloMD database,	CA	N=2,897	E-mail survey to 67,422 MC patients. Demographics	97% reported decreased POM consumed when concurrently using cannabis, 93% prefer

based pain medication: patient self-report	a substitute for opioid and nonopioid-based pain medication		using modified TOPS[1] instrument			, conditions for use, method of ingestion, substitute for POM, non-POM efficacy	cannabis to POM. Clinical outcomes needed for MC as POM substitute; consider MC for treatment of POM dependence.
Shi (2017) Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever	Associations between state MC policy and hospitalizations related to cannabis and POM	Linear time series regression	State inpatient databases, state-level annual admin records of discharges 1997-2014	27 states	382 state-year observation	Rates of hospitalization involving marijuana, opioid, abuse and POM overdose. State, year effects	Medical cannabis legalization was associated with 23% reduction in hospitalizations for opioid abuse or dependence and 13% reduction in POM overdose. MC policies associated with reduced POM related hospitalizations.
Boehnke, Litinas & Clauw (2016) Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain.	Does medical cannabis use for chronic pain changes individual patterns of opioid use	Cross sectional, retrospective survey	Online questionnaire survey	Michigan	N=244 MC dispensary patients with chronic pain who use MC	Demographic, change in opioid use, quality of life, medication classes used, medication side effects before and after MC initiation.	Medical cannabis use associated with 64% decrease in POM use and 45% improvement in quality-of-life. MC for chronic pain may benefit some patients, may improve quality-of-life. Confirm with longitudinal studies
Bradford &	Does	Regression	Medicare	24 states	24 states	Nine clinical	$165.2 million reduction

Bradford (2016) Medical marijuana laws reduce prescription medication use in Medicare part D	Implementing state MC laws change prescribing patterns and expenditures in Medicare Part D	modeling	Part D enrollees from 2010-2013		with medical marijuana law; 9 clinical areas	condition categories covered by state medical cannabis laws, drug data with at least one on-label use	in costs of prescription drugs for which MC could serve as alternative per year in 2013. Availability of MC has significant effect on Medicare Part D expenditures.
Kim et al., (2016) State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers.	Association between MC laws and positive opioid test	Multilevel logistic regression	FARS[2] data from 18 states that tested for alcohol and other drugs	18 states	N=68,394	Fatality analysis data from 18 states in 80% of fatal car accidents.	Significant reduction in opioid positivity for drivers 21-40 years old. MC laws associated with reductions in opioid positivity among 21-to 40-year old fatally injured drivers and may reduce opioid use and overdose.
Sexton, Cuttler, Finnell, & Mischley (2016) A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy	Inform practice, research, and policy, identify between medico-legal and patient outcome discrepancy	Cross-sectional survey	Author developed survey, 44-item, including 10 item PROMIS® global health short form	WA state cannabis dispensary	N=1429	Anonymous online survey, self selected	59.8% substituted for prescriptions 25% substituting for pain meds including opioids. Patient reported outcomes favor MC use for broad diagnoses, largely unsupported by formal research. Discrepancy between approval of MC and actual use.
Powell, Pacula &	Impact of	Differences-	POM abuse	24 states	Multiple	Opioid	Presence of MC

Jacobson (2015) Do medical marijuana laws reduce addictions and deaths related to pain killers?	medical cannabis laws on POM misuse.	in differences, event study, and synthetic control group	treatment admissions TEDS[3], State POM overdose deaths. NVSS[4] ARCOS[5], and NSDUH[6]	with MC laws, 18 with protection against MC dispensary	database	treatment admissions, opioid overdose deaths, non-medical use ARCOS NSDUH	dispensary decreases treatment admissions for POM addiction, reduces deaths due to opioid overdose. Access to MC has potential benefit of reducing POM abuse.
Bachhuber, Saloner, Cunningham & Barry (2014) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010	To determine relationship between state MC laws and POM overdose mortality rate	Time-series analysis; Regression models for state policies	State death certificate and medical cannabis laws, and opioid analgesic overdose mortality	13 states; 1999-2010	3 states with laws prior to study, 10 states with laws initiated during study period	POM overdose deaths	MC laws associated with 24.8% lower state-level POM overdose mortality rates compared to states without. MC may intersect with policies to prevent POM overdose

[1]TOPS: Tilray Observational Patient Survey
[2]FARS: Fatality Analysis Reporting System
[3]TEDS: Treatment Episode Data Set
[4]NVSS: National Vital Statistics System
[5]ARCOS: Automation of Reports and Consolidated Orders System; monitors and records controlled substances
[6]NSDUH: National Survey on Drug Use and Health: state level data on self-reported nonmedical use of prescription pain relievers

OPIOID CRISIS AND CANNABINOIDS

Highlights:

- A staggering number of Americans are dying from overdoses attributed to prescription opioid medications (POMs).

- Alternative therapies are being used for pain management, such as medical cannabis (medical marijuana). However, little is known about how the use of cannabis for pain management may be associated with POM use.

- States that implement medical cannabils policies could reduce POM associated mortality, improve pain management, and significantly reduce health care costs.

- Medical cannabis research is constrained by federal policy restrictions

- Research related to MC as a potential alternative to POM for pain management, MC harms, and its impact on POM related harms and healthcare costs should be a priority of public health, medical, and nursing research